A Study of Remternetug (LY3372993) in Healthy Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07056309
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Remternetug (Test) — DRUG
    Administered SC
  • Remternetug (Reference) — DRUG
    Administered SC

Study Details

The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days.

Key Dates

First listed
Jul 9, 2025
Start date
Jun 24, 2025
Status verified
Jan 2026
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025

Study Design

Enrollment
72 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Remternetug (Test)
    Remternetug administered subcutaneously (SC) via autoinjector (AI)
  • Experimental: Remternetug (Reference)
    Remternetug administered SC via prefilled syringe.

Primary Outcome Measure

Pharmacokinetic (PK): Maximum Concentration (Cmax) of Remternetug [ Time Frame: Predose up to Day 85 ]

Locations (3)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117-
QPS MissouriSpringfieldMissouri65802-
Fortrea Clinical Research UnitDallasTexas75247-

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit· Daytona Beach, FLQPS Missouri· Springfield, MOFortrea Clinical Research Unit· Dallas, TX

Related Studies